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Background. Candidatus Neoehrlichia mikurensis is a newly discovered noncultivatable bacterium spread
among ticks and rodents in Europe and Asia that can infect humans, particularly immunocompromised patients.
Methods. We compiled clinical and laboratory data from 11 patients with hematological malignances or auto-
immune diseases who were diagnosed with Candidatus N. mikurensis infection in Europe 2010–2013. Both pub-
lished (6) and unpublished cases (5) were included.
Results. The patients had a median age of 67, were mostly male (8/11), and resided in Sweden, Switzerland,
Germany, and the Czech Republic. All but one had ongoing or recent immune suppressive treatment and a majority
were splenectomized (8/11). Less than half of them recalled tick exposure. The most frequent symptoms were fever
(11/11), localized pain afﬂicting muscles and/or joints (8/11), vascular and thromboembolic events (6/11), that is,
deep vein thrombosis (4), transitory ischemic attacks (2), pulmonary embolism (1), and arterial aneurysm (1). Typ-
ical laboratory ﬁndings were elevated C-reactive protein, leukocytosis with neutrophilia, and anemia. Median time
from onset of symptoms to correct diagnosis was 2 months. In at least 4 cases, the condition was interpreted to be due
to the underlying disease, and immunosuppressive therapy was scheduled. All patients recovered completely when
doxycycline was administered.
Conclusions. Candidatus N. mikurensis is an emerging tick-borne pathogen that may give rise to a systemic in-
ﬂammatory syndrome in persons with hematologic or autoimmune diseases that could be mistaken for recurrence of
the underlying disease and/or unrelated arteriosclerotic vascular events. Awareness of this new pathogen is warranted
among rheumatologists, hematologists, oncologists, and infectious disease specialists.
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“Candidatus Neoehrlichia mikurensis” was ﬁrst report-
ed to be a human pathogen in 2010 [1–3]. Until now, a
total of 15 cases have been reported from Sweden, [2]
Germany, [3] Switzerland, [1, 4] the Czech Republic,
[5] and China [6]. A little more than half of the pub-
lished cases concerned apparently healthy persons, [1,
3, 6], whereas the remainder were immunocompro-
mised patients [2–5].
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Ca. N. mikurensis received its name in 2004, after it was dis-
covered in ticks and rodents on the Japanese island of Mikura
by means of polymerase chain reaction (PCR) directed against
conserved genes of the bacterial genome, for example, 16SrRNA
and groESL sequences [7]. Transmission electron microscopy of
infected rats showed small cocci in the cytoplasm of endothelial
cells [7]. Phylogenetic analyses reveal it to be a new species be-
longing to the family Anaplasmataceae. Its closest relative is
Candidatus Neoehrlichia lotoris, which primarily infects rac-
coons [8]. Other related species are Ehrlichia ruminantium,
Ehrlichia chaffeensis, and Anaplasma phagocytophilum [7, 9].
All these bacterial species are strict intracellular pathogens
that can only be cultivated in cell lines. N. mikurensis is denom-
inated “Candidatus” because no one to our knowledge has yet
reported its cultivation. The target cells of Neoehrlichia infec-
tion in humans are yet to be deﬁned although polymorphonu-
clear granulocytes [5] and endothelial cells have been implicated
[9].At present, the only diagnostic option is either pan-bacterial
PCR (targeting the 16S rRNA gene) followed by sequence anal-
ysis, [2] or a speciﬁc real-time polymerase chain reaction (RT-
PCR), [4] performed on whole blood, plasma, or bone marrow.
No serological tests are available, and the lack of serological
cross-reactivity with either Anaplasma phagocytophilum or
Ehrlichia chaffeensis [3, 7] precludes the use of Anaplasma- or
Ehrlichia-based indirect ﬂuorescence antibody tests.
In retrospect, it has become clear that others have reported
on the same bacterial species prior to Kawahara’s original report
from 2004 but under other names [10–15].Ca. N. mikurensis is
widely distributed among ticks (Ixodes ricinus, I. persulcatus,
I. ovatus, I. frontalis), [8, 16] rats, ﬁeld mice, and voles in North-
ern [12,17, 18],Central [19–22], and Eastern Europe [16, 23, 24],
Asia [7, 25, 26], and Africa [27].No reports exist from the Amer-
icas or Australia. Rodents appear to be healthy carriers of
Ca. N. mikurensis and may be viewed as the zoonotic reservoir
[17, 28]. The only other animal species besides humans that has
been shown to become sick due to Ca. N. mikurensis infection
are dogs [29].
One peculiarity of Neoehrlichia infection in humans is the ac-
cumulation of cases among patients with B-cell malignancies or
rheumatological diseases, many of whom have been splenecto-
mized [2, 4, 5]. Another distinguishing feature is the high prev-
alence of thromboembolic complications among these patients
[2–4]. Importantly, diagnosis of infection could be missed or se-
verely delayed as the clinical picture of Neoehrlichia infection
may be misinterpreted as noninfectious conditions, for exam-
ple, arteriosclerotic thromboembolism with secondary fever,
or systemic inﬂammation due to a new bout or recurrence of
the underlying rheumatologic or hematologic disease.
The objective of this study was to provide a synopsis of new,
unpublished cases of Neoehrlichia infection in patients with
rheumatic/autoimmune diseases or hematologic malignancies
(n = 5) along with already published cases (n = 6) regarding
host factors, clinical picture, and laboratory ﬁndings. The goal
is to make rheumatologists, hematolo/oncologists, and infec-
tious disease specialists aware of this new infectious disease as
patients may remain untreated, or even worse, be given chemo-
therapy and/or immune suppressive therapy against the under-
lying disease.
METHODS
Data Collection
All but 1 of the 6 Swedish patients reside on the west coast of
Sweden, within a 100 km-radius from the city of Göteborg.
They attend the rheumatology and/or hematology clinics at
the Sahlgrenska University Hospital in Göteborg and Kungälv’s
Hospital. One patient was treated at Karlstad’s Hospital. The
Swedish patients have given oral or written consent to publish
nonidentiﬁable data. Some of the patients participate in the
“Neo-VÄST” study, which was approved by the Local Ethics
Committee in Göteborg, Sweden.
The details on the origin, clinical recruitment, and follow-up
of all other patients summarized here have been reported else-
where [3–5].
Procedures
Clinical data have mainly been derived from the patients’ jour-
nals and attending physicians in charge of the respective pa-
tients; anamnestic data were derived from the patients
themselves. Some data were obtained from published patient
cases [2–5]. Laboratory data were also obtained from patient
charts and published case reports. GraphPad prism 5.0 software
was used to calculate medians and 25/75 percentiles.
The diagnosis of Ca. N. mikurensis infection was in all cases
based on PCR analysis of peripheral blood samples followed by
sequence analysis. Specimens of bone marrow, cerebrospinal
ﬂuid, and blood culture ﬂask contents were also tested for the
presence of Neoehrlichia DNA. Pan-bacterial PCR directed
against either the V1–V4 region (Sweden, Germany, Switzer-
land) [2–4] or V4–V8 region (Czech Republic) [5] of the 16S
rRNA-gene was used to amplify bacterial DNA. Taqman-
based real-time PCR assays targeting either parts of the groEL
gene or the 16 SrRNA gene [2–4] of Ca. N. mikurensis, incor-
porating internal control plasmids containing the same respec-
tive gene sequences, were used to estimate the concentrations of
bacterial gene copies in patients’ samples.
Statistical Analyses
Statistical analyses were not performed because there was no
control group for comparative analyses.
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Role of Funding Source
The funding sources (Västra Götaland Regional Research and
Development Fund, ALF Research Fund, and Cancer and Aller-
gy Foundation) are noncommercial organizations that have had
no impact on the design of the present study.
RESULTS
Host Factors
The 11 patients were all middle-aged or elderly (median age 67
years, range 54–77) and had an underlying disease involving the
adaptive immune system (Table 1). More speciﬁcally, the pa-
tients had either malignant clonal expansion of lymphocytes,
in most cases malignant lymphoma or chronic lymphocytic leu-
kemia engaging B cells, or clonal expansion of autoreactive
lymphocytes, giving rise to autoimmune diseases such as rheu-
matoid arthritis, systemic lupus erythematosus, or psoriasis
(Table 1). Three patients ﬁrst had an autoimmune disease
and subsequently also developed a malignant hematological
disease (patients 3, 4, and 6). A surprisingly high fraction of
the patients (73%) had no spleen; in most instances it had
been removed to diagnose the suspected hematologic disease
(Table 1). Also, a majority of the patients had ongoing or recent
(preceding 3 months) chemotherapy or immunosuppressive
treatment with systemic corticosteroids and/or rituximab
(anti-CD20 monoclonal antibody).
Symptoms and Clinical Signs
All patients had systemic inﬂammation, manifested as high
fever, often spiking up to 40°C, with chills and nightly sweats
(clinical signs are shown in Table 2). Another prominent ﬁnding
was different types of localized pain, such as migrating muscular
pain, stiff neck, tender subcutaneous veins, and joint pain engag-
ing knees, mandibular/temporal joints, and elbows—2 of the pa-
tients with myalgia and arthralgia required opiates because the
pain was not relieved by corticosteroid treatment. All but one of
the patients were hospitalized, and 2 were admitted more than
once until the correct diagnosis was established.
The most striking ﬁnding was the high rate of vascular and
thromboembolic events associated with this infectious disease.
More than half of the patients were afﬂicted (6/11), and some of
them severely: 2 patients had deep vein thrombosis above the
knee, a third patient developed deep vein thrombosis twice
(upper arm and leg), and another patient developed deep vein
thrombosis, pulmonary embolism, and transitory ischemic at-
tacks. The 2 patients with transitory ischemic attacks had re-
peated episodes that engaged both sides of the body. One
patient had severe arterial inﬂammation with aneurysms.
Table 1. Host Factors of 11 Patients Diagnosed With Candidatus Neoehrlichia mikurensis Infection
Patient Age Sex
Hematological
Malignancy Autoimmune disease Immune Suppression Asplenic
Date of
Diagnosis Country Reference
1 77 M B-CLL Corticosteroids Yes July 2009 Sweden [2]
2 75 M B-CLL Azathioprine
Corticosteroids
Yes July 2011 Sweden This study
3 67 F Later developed
Follicular
lymphoma
SLE Corticosteroids Yes (inborn) July 2011 Sweden This study
4 67 F T-LGL Psoriasis artropathy Cyclophosphamide
Corticosteroids
Yes January 2013 Sweden This study
5 54 M None Psoriasis Cyclophosphamide
Corticosteroids
No January 2013 Sweden This study
6 59 M DLCBL Rheumatoid arthritis Cyclophosphamide Yes June 2013 Sweden This study
7 68 M CLL Rituximab
Corticosteroids
Yes October 2011 Switzerland [4]
8 58 M Follicular
lymphoma
Rituximab No October 2011 Switzerland [4]
9 55 F Mantle cell
lymphoma
Rituximab
Cytosinarabinoside
Mitoxantrone
Methothrexate
Yes March 2008 Czech
Republic
[5]
10 58 M PTLD Sclerosing cholangitis Rituximab Tacrolimus Yes July 2009 Czech
Republic
[5]
11 69 M None Chronic inflammatory
demyelinating
polyneuropathy
Rituximab
Cyclophosphamide
Corticosteroids
No June 2007 Germany [3]
Abbreviations: B-CLL, B-cell chronic lymphocytic leukemia; CLL, Chronic Lymphocytic Leukemia; DLCBL, Diffuse large cell B-cell lymphoma; F, female; M, male;
PTLD, post transplant lymfoproliferative disorder; SLE, Systemic lupus erythematosus; T-LGL, T-cell large granular lymphocyte lymphoma/leukemia.
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Possibly, the ankle swelling observed among several patients re-
ﬂected local blood vessel inﬂammation. Two patients who did
not develop any vascular or thromboembolic events were on
prophylactic anticoagulation treatment at the time of diagnosis
(patient 4, low-dose aspirin because of atrial ﬁbrillation; pa-
tient 6, chronic low-molecular heparin because of repeated
DVT and pulmonary embolism). Hence, multiple thromboem-
bolic events seem to characterize Ca. N. mikurensis infection.
Less speciﬁc ﬁndings displayed by some patients were skin
rashes of the lower extremities, that is, erythema nodosum
and erysipelas, and diarrhea. Signiﬁcant weight loss developed
in a few patients, particularly those with systemic inﬂammation
of long duration. Pulmonary symptoms such as cough were dis-
crete and infrequent, and the majority of patients lacked pulmo-
nary inﬁltrates on chest radiograms.
Laboratory Findings
The most abnormal laboratory ﬁndings among the routine
parameters that are usually analyzed in patients with systemic
inﬂammation are listed in Table 3. The only consistent ﬁnding
among all patients was elevation of the acute phase reactant
C-reactive protein in serum, with levels ranging from 4- to 74-
fold higher than the cutoff level. Leukocytosis with neutrophilia
and anemia were also typical ﬁndings. About half of the patients
had at some point raised levels of lactate dehydrogenase in serum
and hyponatremia, respectively. Lowered platelet counts and
elevated transaminase concentrations were rare ﬁndings.
Diagnostics and Bacterial Load
The diagnosis of Ca. Neoehrlichia infection was in all cases
based on pan-bacterial PCR analysis of segments of the 16S
rRNA gene followed by sequence and homology analyses.
EDTA- or citrate-anticoagulated peripheral blood samples
were uniformly used for diagnosis, but Neoehrlichia DNA was
also detected in plasma specimens (most patients), blood cul-
ture ﬂask contents (patient 1) and in bone marrow samples
(patients 7, 8, and 11). However, Neoehrlichia was not detected
in cerebrospinal ﬂuid of patient 3 despite neurologic symptoms;
these symptoms were interpreted to result from infection-
related transitory ischemic attacks.
Indirect estimates of the concentrations of bacteria in patient
samples were performed using real-time PCR and internal con-
trol plasmids. If one assumes that Neoehrlichia contains only 1
copy of the 16S rRNA gene or heat shock protein gene groEL,
bacterial concentrations were on the order of 106/mL blood
among these patients (median value of 2 × 106 bacterial gene
copies/mL in 5 assessed patients, 25/75 percentile = 0.05–
7.8 × 106/mL). The levels were even higher in bone marrow:
up to 35 × 107/mL (patient 7).
Diagnostic Delay
Diagnostic delay was considerable, the median number of days
from the onset of symptoms to diagnosis was 60 (25/75 percen-
tile = 26–135). All patients were subjected to extensive microbi-
ological investigations and given empiric antibiotics. Some
patients received corticosteroids because of suspected “disease
fever”, for example, “tumor fever” or “autoimmune fever.” At
least 4 of the patients had been scheduled to receive chemotherapy
but narrowly escaped such treatment once Ca. N. mikurensis in-
fection was diagnosed. Five of the 11 patients recalled tick bites.
Three patients fell ill during winter/early spring (January–
March in Europe), one of whom (patient 4) received blood trans-
fusions prior to development of infectious symptoms (Table 1).
Response to Antibiotics
All patients had been given empiric antibiotics treatment other
than doxycycline before the diagnosis of Ca. N. mikurensis in-
fection was set. No response was seen to benzyl-penicillin or pi-
peracillin/tazobactam, amoxicillin ± clavulanate, clindamycin,
third-generation cephalosporines (cefotaxime, ceftazidime),
aminoglycosides (gentamicin), or quinolones (ciproﬂoxacin
and levoﬂoxacin). A transient response to meropenem was
seen in a few cases. A complete response was achieved in all pa-
tients once they were treated with doxycycline (100 mg PO
BID) for 3–6 weeks. Many patients experienced dramatic and
rapid improvement within 1 day of initiation of doxycycline
therapy. The median time to resolution of symptoms was 5
days (25/75 percentile = 2–8).
Table 2. Clinical Signs of 11 Patients Diagnosed With
Neoehrlichiosis
Clinical Sign No. of Patients Percent
Fever 11/11 100
Chills 7/11 64
Nightly sweats 5/11 45
Pain 8/11 73
Muscular 4/11 36
Neck 3/11 27
Mandible 3/11 27
Subcutaneous veins 2/11 18
Arthralgia 2/11 18
Vascular/ thromboembolic events 6/11 54
Deep vein thrombosis 4/11 36
Transitory ischemic attack 2/11 18
Pulmonary embolism 1/11 9
Arterial aneurysm 1/11 9
Skin rash 4/11 36
Erythema nodosum 2/11 18
Erysipelas 2/11 18
Ankle edema 4/11 36
Cough 4/11 36
Weight loss 4/11 36
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DISCUSSION
The purpose of this case review study was to highlight one rea-
son for why human cases of Neoehrlichia infection may go
unrecognized: the aberrant clinical picture seen among 2 partic-
ular groups of patients–middle-aged persons with autoimmune
diseases or hematologic malignancies. First, myalgia, arthralgia,
and/or fever are typical ﬁndings among patients with some of
the autoimmune conditions described in this study, for exam-
ple, psoriasis arthropathy, rheumatoid arthritis, or systemic
lupus erythematosus. Second, if no infectious agents are discov-
ered despite extensive microbiological investigations in patients
with fever and systemic inﬂammation with a serious underlying
condition, such as malignant lymphoma, chronic lymphatic
leukemia, or autoimmune systemic rheumatic disease, the
most common interpretation is that the condition reﬂects recur-
rence/deterioration of the underlying morbidity. This may ulti-
mately result in erroneous, and potentially dangerous,
administration of immune suppressive therapy such as chemo-
therapy, rituximab, and corticosteroids, which almost occurred
in at least 4 of the cases documented in this study.
Another common ﬁnding among the Neoehrlichia-infected
patients was the high incidence of thromboembolic/vascular
complications; these were not interpreted to be the consequence
of an infection but coincidental to a systemic inﬂammatory con-
dition of unknown cause. In one case, fever was suspected to be
secondary to widespread venous embolism [2]. As transitory is-
chemic attacks are quite common among older persons, it is un-
derstandable that this complication was initially seen as a
separate phenomenon, not connected to the febrile episode.
Finally, we report a case of arterial aneurysm in a Neoehrli-
chia-infected patient with underlying autoimmune disease. Al-
though it is impossible to attribute causality between the
development of the aneurysm and Neoehrlichia infection,
there has been a previous report of cerebral arterial aneurysm
in a purported previously healthy person with suspected
Neoehrlichia infection, who actually died from intracerebral
hemorrhage [3].
The pathogenic mechanisms behind the thromboembolic
complications associated with Neoehrlichia infection are un-
known. Is it a direct effect of infection? Does Neoehrlichia infect
endothelial cells or exert toxic effects on the endothelium? Or is it
an indirect effect of long-standing systemic inﬂammation with
concomitant activation of coagulation [30]?Blood clot formation
is a primitive infectious defense mechanism used by horse shoe
crabs and other invertebrates to limit infectious processes [30];
the high rate of thromboembolic complications in our patients
may have been the next best alternative for those with depressed
B-cell immune responses to curb the infectious process.
The importance of the spleen in the infectious defense against
Neoehrlichia is reﬂected by the high prevalence of splenectomized
patients in this study. The well-known function of the spleen in
the defense against encapsulated bacteria is not likely to be of rel-
evance for Ca. Neoehrlichia mikurensis with its frail cell wall [7].
Instead, the spleen’s importance for the generation of “natural
antibodies” [31] and maintenance of immunoglobulin M (IgM)
memory B cells [32] is probably more pertinent. The very high
loads of bacteria in the blood of patients most likely reﬂect
their impaired immune state. However, no patient died despite
the fact that diagnostic delay was signiﬁcant. Moreover, the
patients recovered within a week after doxycycline therapy was
initiated. It appears as if 100 mg doxycycline twice daily for a
3-week period is sufﬁcient to clear the infection.
There are several more reasons for the paucity of reported
human Neoehrlichia cases: (1) the bacterium does not grow in
cell-free media. In fact, to date no one to our knowledge has yet
succeeded in cultivating the bacterium at all, which requires the
use of eukaryotic cell lines. Hence, the diagnosis relies on pan-
bacterial or speciﬁc PCR, which are not used as ﬁrst-line diag-
nostic procedures. (2) Awareness of this newmicrobe is very low
among medical practitioners. (3) Some of the symptoms arising
from a Neoehrlichia infection may be attributed to other
Table 3. Laboratory Parameters of 11 Patients Diagnosed With Neoehrlichiosis
Laboratory Parameter Level Range of Altered Parameter Reference Level Unit No. of Patients Percent
S-C-reactive protein ↑ 19–370 <5 g/L 11/11 100
White blood cell count ↑ 11–26 3.5–8.8 ×109/L 9/11 82
B-Neutrophils ↑ NR 1.8–7.5 ×109/L 9/11 82
B-Hemoglobin ↓ 85–119 117–170 g/L 9/11 82
S-Sodium ↓ 127–136 137–145 mmoles/L 6/11 54
S-Lactate dehydrogenase ↑ 3.9–15 1.8–3.4 µcat/L 5/11 45
B-platelet counts ↓ Slight decrease 145–348 ×109/L 2/11 18
S-Aspartate aminotransferase ↑ Slight increase (<2-fold) (0.25–0.75) µcat/L 2/11 18
S-Alanine aminotransferase ↑ Slight increase (<2-fold) (0.15–1.1) µcat/L 2/11 18
Abbreviations: B, blood; NR, not reported; S, serum.
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infectious agents such as Borrelia, Anaplasma or a random
“summer virus”. Doxycycline, the treatment of choice for Neo-
ehrlichia infection, is equally efﬁcient to treat infections per-
ceived to be caused by Borrelia, Anaplasma, and Ehrlichia
species, respectively. We propose the use of the term “neoehrli-
chiosis” as a complement to the longer “Candidatus Neoehrli-
chia mikurensis” infection, both in the interest of brevity, but
also to focus on this new clinical infectious disease. Moreover,
this nomenclature has already been used elsewhere [4].
The most likely route of transmission of the infection to hu-
mans is direct inoculation of the bacteria through the skin via
the bite of infected ticks. The incubation period is unknown but
has been estimated to be 5–21 days for the other human path-
ogenic ehrlichiae [33]. The fact that more than half of the pa-
tients were unaware of tick bite is in agreement with studies
of Borrelia, where it is well-known that tick bites may pass un-
noticed by patients [34]. Three patients apparently fell ill during
winter/early spring, which was surprising as ticks are less active
during this period of the year. Because one of the patients had
received blood transfusions prior to the development of fever,
we investigated if this might have been the route of transmis-
sion, as has been shown for Anaplasma [35] and Ehrlichia
[36]. Unfortunately, no aliquot from the erythrocyte concen-
trate had been stored. One of the 2 blood donors claimed to
have had a ﬂulike episode prior to donation of blood; this
donor tested negative for Neoehrlichia DNA but had recovered
completely and was asymptomatic at the time of testing. Thus,
we were unable to determine if blood transfusions are a possible
route of Neoehrlichia infection.
To conclude, we hope to raise the awareness of this newly dis-
covered microbe that may give rise to an infectious disease in
elderly persons with autoimmune conditions and hematological
malignancies. Physicians within the ﬁelds of rheumatology, he-
matology, oncology, and infectious diseases should be aware of
this new infectious agent and their attention drawn to patients
with suspected recurrence of the underlying autoimmune or he-
matologic disease where the clinical picture is atypical.
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